Inventor · disambiguated record
Renhong Tang
Also filed as: TANG RENHONG
3 granted patents·31 pending applications·0 citations·filing 2020–2025
49Inventor score
Files withSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD8SIMCERE ZAIMING PHARMACEUTICAL CO LTD7HAINAN SIMCERE PHARMACEUTICAL CO LTD4JIANGSU SIMCERE PHARM CO LTD4NANJING ZAIMING PHARMACEUTICAL CO LTD4
Top patents by PatentIndex Score
34 records- 0177US12319725B2IL-2 mutant and application thereofHAINAN SIMCERE PHARMACEUTICAL CO LTD·Filed 2024·Granted Jun 3, 2025·0 cites·16 claims
- 0275US2025382343A1Il-2 Mutants And Uses ThereofHAINAN SIMCERE PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 0372US2024209051A1Il-2 Mutant And Application ThereofHAINAN SIMCERE PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0465US12421286B2Il-2 mutant and application thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2021·Granted Sep 23, 2025·0 cites·14 claims
- 0559US2025122221A1Six-membered cyclothiazole compound and use thereofNANJING ZAIMING PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0659US2025304717A1Camptothecin derivative and ligand-drug conjugateHAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0754US2025270227A1Camptothecin derivative, and pharmaceutical composition and use thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0853US2024124454A1Tricyclic compound and use thereofNANJING ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 0953US2025009847A1Il-15 mutant fusion protein pharmaceutical compositionSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1053US2025186550A1Pharmaceutical composition of il2 mutant-antibody fc block fusion protein and use thereofHAINAN SIMCERE PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1151US2024343803A1Anti-Pvrig/Anti-Tigit Bispecific Antibodies And Applications ThereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1251US2024124575A1Human cd33 antibody and use thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1350US2025075006A1Anti-gucy2c nano-antibody and application thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1450US2024307415A1Steroid compound, and pharmaceutical composition thereof and use thereofJIANGSU SIMCERE PHARM CO LTD·Filed 2022·Application pending·0 cites
- 1550US2025297021A1Bcma antibody and use thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO NO 1·Filed 2022·Application pending·0 cites
- 1649US2024343811A1Cd16 antibody and use thereofSHANDONG SIMCERE BIOPHARMACUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1749US2025297030A1Anti-muc17 nanobody and use thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1849US2025042994A1Cd19 antibody and application thereofHAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1949US2025145705A1Gprc5d antibody and application thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2048US2025136687A1Anti-human cd3 antibody and use thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2147US2024084003A1Anti-human cd22 monoclonal antibodies and use thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2247US2025179172A1Cd5 antibody and use thereofHAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 2347US2024109974A1Humanized antibody against tnfr2 and use thereofJIANGSU SIMCERE PHARM CO LTD·Filed 2022·Application pending·0 cites
- 2446US2023416360A1Anti-cd22 nano antibody and use thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 2546US2025250357A1Anti-msln antibody and application thereofNANJING ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2646US2025026844A1Anti-bcma nanobody and use thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2745US2023250108A1Tetrahydroisoquinoline compounds and use thereofJIANGSU SIMCERE PHARM CO LTD·Filed 2021·Application pending·0 cites
- 2844US2023192797A1Human il-15 mutant and uses thereofJIANGSU SIMCERE PHARM CO LTD·Filed 2021·Application pending·0 cites
- 2944US2023142274A1Substituted aryl compoundSimcere pharmaceutical co ltd·Filed 2021·Application pending·0 cites
- 3043US2024076403A1Her2 antibody and application thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3141US2024124563A1Anti-Human MSLN Antibody And Application ThereofNANJING ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3240US2024052055A1Gpc3 antibody and application thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3340US2024101686A1Anti-egfr nanobody and use thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3431US12365730B2Anti-CD79B antibody, antigen-binding fragment thereof, and pharmaceutical use thereofTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2020·Granted Jul 22, 2025·0 cites·22 claims
Join the waitlist — get patent alerts
Get an alert when Renhong Tang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →